top of page
BARD: A seamless two-stage dose optimization design integrating backfill and adaptive randomization
Date: August 22, 2025 PMID: PMC12240483 Category: N/A Authors: Yixuan Zhao, Rachael Liu, Jianchang Lin, Ying Yuan Abstract: 40626646 One common approach for dose optimization is a two-stage design, which initially conducts dose escalation to identify the maximum tolerated dose, followed by a randomization stage where patients are assigned to two or more doses to further assess and compare their risk-benefit profiles to identify the optimal dose. A limitation of this approach
bgtaylor1
Nov 11, 20252 min read
Pancreatic islet β-cell subtypes are derived from biochemically-distinct and nutritionally-regulated islet progenitors
Date: July 1, 2025 PMID: PMC12217943 Category: N/A Authors: Monica E Brown, Verda E Miranda, Simone Nevills, Ruiying Hu, Prasanna K Dadi, Alan J Simmons, Yanwen Xu, Yilin Yang, Mahircan Yagan, Sadia Najam, Leesa L Sampson, Mark A Magnuson, David A Jacobson, Ken S Lau, Emily Hodges, Guoqiang Gu Abstract: 40593675 Endocrine islet β cells comprise heterogenous subtypes with different gene expression and function levels. Here we study when/how this heterogeneity is induced and ho
bgtaylor1
Nov 11, 20252 min read
Performance of the Oncuria-Detect bladder cancer test for evaluating patients presenting with haematuria: results from a real-world clinical setting
Date: June 18, 2025 PMID: PMC12178018 Category: N/A Authors: Ian Pagano, Zhen Zhang, Michael Luu, Sergei Tikhonenkov, Florence Le Calvez-Kelm, Steve Goodison, Toru Sakatani, Kaoru Murakami, Takashi Kobayashi, Patrice Avogbe, Howard Kim, Riko Lee, Arnaud Manel, Emmanuel Vian, Charles J Rosser, Hideki Furuya Abstract: 40533776 Background: Bladder cancer is the 9th most diagnosed cancer worldwide with high incidences reported in Europe and the United States. Here, we evaluated t
bgtaylor1
Nov 11, 20252 min read
bottom of page